TERT rs2853676 polymorphisms correlate with glioma prognosis in Chinese population
Metrics: PDF 1073 views | HTML 1510 views | ?
Xue He1,2,3,*, Yahui Wei4,*, Zhengshuai Chen5, Xikai Zhu1,2,3, Lifeng Ma1,2,3, Ning Zhang5, Yuan Zhang1,2,3, Longli Kang1,2,3, Dongya Yuan1,2,3, Zongyong Zhang6, Tianbo Jin1,2,3,5
1Key Laboratory for Molecular Genetic Mechanisms and Intervention Research on High Altitude Disease of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang, 712082 Shaanxi, China
2Key Laboratory for Basic Life Science Research of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang, 712082 Shaanxi, China
3Key Laboratory of High Altitude Environment and Gene Related to Disease of Tibet Ministry of Education, School of Medicine, Xizang Minzu University, Xianyang 712082, Shaanxi, China
4Central Hospital of Xianyang, Xianyang 712000, Shannxi, China
5National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an, 710069 Shaanxi, China
6Life Science Research Centre of Taishan Medical University, Taian, 271016 Shangdong, China
*Joint first authors
Zongyong Zhang, email: [email protected]
Tianbo Jin, email: [email protected]
Keywords: glioma, TERT, rs2853676, overall survival, progress-free survival
Received: May 30, 2016 Accepted: September 02, 2016 Published: September 16, 2016
High rates of recurrence and the lack of effective treatments contribute to the poor prognosis of patients with glioma. There is therefore an urgent need for an easily detectable biomarker to facilitate early detection. In this study, we explored the association between TERT rs2853676 genetic polymorphisms and the prognosis of Chinese glioma patients. A total of 481 glioma patients at the Tangdu Hospital of the Fourth Military Medical University in China were included in this study. The overall survival rates were calculated using the Kaplan-Meier method. Prognostic factors were determined through multivariate Cox regression analysis. The overall survival (OS) rates of one, two, and three years were 31%, 10.3%, and 7.5%, respectively. The progress-free survival (PFS) rates of one, two, and three years were 15.7%, 7.3%, and 4.7%, respectively. The genotype “A/G” of TERT rs2857676 decreased the PFS rate (hazard ratios [HR] = 0.824; P = 0.059). The genotype “A/G (HR = 0.803; 95% CI, 0.656 – 0.982; P = 0.032)” and “A/A + A/G” decreased the recurrence rate compared to the genotype G/G (HR = 0.818; 95% CI, 0.675-0.99; P = 0.040). Our study indicates that TERT rs2853676 polymorphisms correlate with glioma survival and recurrence rates in a Chinese population, which suggests that they could potentially serve as prognostic markers in glioma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.